Rifloc Retard en es it fr

Rifloc Retard Brand names, Rifloc Retard Analogs

Rifloc Retard Brand Names Mixture

  • No information avaliable

Rifloc Retard Chemical_Formula

C6H8N2O8

Rifloc Retard RX_link

http://www.rxlist.com/cgi/generic2/isodinit.htm

Rifloc Retard fda sheet

Rifloc Retard msds (material safety sheet)

Rifloc Retard Synthesis Reference

Goldberg, Acta physiol. Scand.15, 173(1948)

Rifloc Retard Molecular Weight

236.136 g/mol

Rifloc Retard Melting Point

70 oC

Rifloc Retard H2O Solubility

1.089 mg/mL

Rifloc Retard State

Solid

Rifloc Retard LogP

-0.53

Rifloc Retard Dosage Forms

Oral tablet

Rifloc Retard Indication

For the prevention of angina pectoris due to coronary artery disease.

Rifloc Retard Pharmacology

Isosorbide Dinitrate is a moderate to long acting oral organic nitrate used for the relief and prophylactic management of angina pectoris. It relaxes the vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end- diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure.

Rifloc Retard Absorption

Absorption of isosorbide dinitrate after oral dosing is nearly complete, but bioavailability is highly variable (10% to 90%), with extensive first-pass metabolism in the liver. The average bioavailability of isosorbide dinitrate is about 25%.

Rifloc Retard side effects and Toxicity

Symptoms of overdose include reduced cardiac output and hypotension.

Rifloc Retard Patient Information

PATIENT INFORMATION

Patients should be told that the anti-anginal efficacy of isosorbide dinitrate is strongly related
to its dosing regimen, so the prescribed schedule of dosing should be followed carefully. In
particular, daily headaches sometimes accompany treatment with isosorbide dinitrate. In patients
who get these headaches, the headaches are a marker of the activity of the drug. Patients should
resist the temptation to avoid headaches by altering the schedule of their treatment with isosorbide
dinitrate, since loss of headache may be associated with simultaneous loss of anti-anginal efficacy.
Aspirin and/or acetaminophen, on the other hand, often successfully relieve isosorbide dinitrate-
induced headaches with no deleterious effect an isosorbide dinitrate's anti-anginal efficacy.

Treatment with isosorbide dinitrate may be associated with lightheadedness on standing, especially
just after rising from a recumbent or seated position. This effect may be more frequent in patients
who have also consumed alcohol

Rifloc Retard Organisms Affected

Humans and other mammals